CN105010937A - L-arabinose anti-alcohol pill and preparation method thereof - Google Patents
L-arabinose anti-alcohol pill and preparation method thereof Download PDFInfo
- Publication number
- CN105010937A CN105010937A CN201510488054.1A CN201510488054A CN105010937A CN 105010937 A CN105010937 A CN 105010937A CN 201510488054 A CN201510488054 A CN 201510488054A CN 105010937 A CN105010937 A CN 105010937A
- Authority
- CN
- China
- Prior art keywords
- arabinose
- parts
- tablet
- drunk
- sobering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 title abstract 7
- 239000006187 pill Substances 0.000 title abstract 7
- 230000002075 anti-alcohol Effects 0.000 title abstract 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 17
- 235000004279 alanine Nutrition 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 13
- 239000000845 maltitol Substances 0.000 claims abstract description 13
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims abstract description 13
- 229940035436 maltitol Drugs 0.000 claims abstract description 13
- 235000010449 maltitol Nutrition 0.000 claims abstract description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 40
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001479 arabinose derivatives Chemical class 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000008901 benefit Effects 0.000 abstract description 3
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 2
- 229930182816 L-glutamine Natural products 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 239000008279 sol Substances 0.000 description 7
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 244000046146 Pueraria lobata Species 0.000 description 4
- 235000010575 Pueraria lobata Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- -1 obtains 15 Substances 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses an L-arabinose anti-alcohol pill and a preparation method thereof. According to the L-arabinose anti-alcohol pill, L-arabinose, L-glutamine and alanine serve as main ingredients, and croscarmellose sodium, microcrystalline cellulose, magnesium stearate and maltitol serve as auxiliary ingredients; the L-arabinose anti-alcohol pill comprises, by weight, 10-60 parts of L-arabinose, 5-15 parts of L-glutamine, 2-10 parts of alanine, 2-8 parts of croscarmellose sodium, 1-5 parts of microcrystalline cellulose, 0.3-3 parts of magnesium stearate and 5-50 parts of maltitol. The L-arabinose anti-alcohol pill has the advantages of being convenient to carry and take and good in taste and effect, meanwhile, no pigment or cane sugar is contained in the product, the pill is safe to take, no toxic or side effect exists, and the pill is assured for diabetes to eat.
Description
Technical field
The present invention relates to Medicines and Health Product technical field, specifically a kind of Arabinose drunk-sobering tablet and preparation method thereof.
Background technology
Arabinose is a kind of five-carbon ring aldehydo sugar, it is a kind of novel low calorie sweetener, within 1998, be used as antiadipositas drug thing or nutritious supplementary pharmaceutical by U.S. FDA approval, calendar year 2001 is approved as the food specific for health care and healthy food additive that regulate blood sugar by Japanese health ministry, within 2008, Arabinose is approved as new resource food by China, therefore, Arabinose is a kind of medicine-food two-purpose product human body to critical function effect.According to verification experimental verification, after Arabinose enters human body, can the activity of acetaldehyde dehydrogenase in human activin, play the effect of acetaldehyde-dehydrogenase enzyme auxiliary agent, accelerate acetaldehyde and resolve into acetic acid rapidly in human body, play liver-protective effect.And alcohol metabolic process in vivo, a small amount of after entering human body, breathe with lung at once or excrete through sweat gland, the overwhelming majority enters liver, be acetaldehyde (harmful) by alcohol dehydrogenase by ethanol conversion in liver, be acetic acid (harmless) by acetaldehyde dehydrogenase by converting acetaldehyde further again, therefore say, after people drinks, converting acetaldehyde is that the speed of acetic acid determines the extent of injury of alcohol to human liver, if acetaldehyde can not be converted into acetic acid rapidly, then very serious to the damage of liver, in other words, the height of aldehyde dehydrogenase activity in human body, determine the extent of damage of alcohol to human liver, because Arabinose can the activity of acetaldehyde dehydrogenase in human activin, play the effect of acetaldehyde-dehydrogenase enzyme auxiliary agent, so Arabinose has the function of relieving the effect of alcohol.
Disintoxicating product is prepared about utilizing Arabinose, disclose in the Chinese patent literature of publication number CN101797279B " a kind of health products with antialcoholism action ", it is made up of Arabinose and kudzuvine root total powder, capsule or tablet is made by pulverizing, mixing, sieve, this series products is furnished with the medicinal herb components root of kudzu vine, poorly soluble, coarse mouthfeel, consumers in general are beyond affordability.
And the solution alcohol product sold in the market is mainly with turmeric, the root of kudzu vine, the Chinese medicine preparations such as oyster are principal component, Chinese patent as publication number CN101919802A discloses one " buccal absorption solid relieve the effect of alcohol effervescent formulation ", its composition and effectiveness is by natural caffeine and haw thorn extract, green-tea extract, trifoliate orange seed extract, Semen Myristicae extract, tuckahoe extracts, Fructus Tsaoko extract, kudzu root extract, Wild jujube seeds extract, Ramulus Cinnamomi extract, galangal rhizome extract, one or several compositions of chrysanthemum extract, be aided with basic component simultaneously, acidic components, lapping and auxiliary material, make the effervescent formulation that relieves the effect of alcohol, its mechanism of relieving the effect of alcohol utilizes traditional Chinese medicine ingredients decomposing alcohol, but twice decomposition onset is slow, often do not reach effect, and metabolism can be caused to bear to liver kidney while relieving the effect of alcohol, do not advise long-term taking.
Glu, alanine are all take glucose as raw material; through human body necessary amino acid every day prepared by biological fermentation process, proterties is white crystals or crystal powder, soluble in water; odorless; nontoxic, there is micro-sweet taste, nutritional supplement, blending enriching substance can be made in food processing; after human body is edible, safety is free of a burden; wherein Glu can be protected and repair the gastrointestinal tract mucosa of damage, strengthens body mechanical barrier function, reduces the trap of alcohol in stomach and intestine.Meanwhile, can get involved synthesizing glutathion, the fatty liver that suppression ethanol infringement liver produces, increase biosynthesis and the storage of glutathione, protection liver function, and then increase the activity of alcohol dehydrogenase in body, acceleration of alcohol decomposition excretes.Alanine can promote metabolism, it is reported, alanine is pantothenic acid synthesis precursor, produce a large amount of pantothenic acid in vivo, pantothenic acid is the coenzyme of NAD+, and the increase of pantothenic acid facilitates ethanol metabolism in vivo, that is, in time the alcohol metabolism in body can be fallen, alleviate the infringement to liver.
Summary of the invention
Technical assignment of the present invention is to provide a kind of Arabinose drunk-sobering tablet and preparation method thereof.
Technical assignment of the present invention realizes in the following manner, this Arabinose drunk-sobering tablet is with Arabinose, Glu and alanine for major ingredient, with Ac-Di-Sol, microcrystalline cellulose, dolomol and maltitol for auxiliary material is prepared from;
Formulation weight part proportioning of described major ingredient and auxiliary material is as follows:
Arabinose 10-60 parts, Glu 5-15 parts, alanine 2-10 parts, Ac-Di-Sol 2-8 parts, microcrystalline cellulose 1-5 parts, dolomol 0.3-3 parts, maltitol 5-50 parts.
Preparation method's step of this Arabinose drunk-sobering tablet is as follows:
Following procedure of processing is carried out in the clean area of purification:
Step 1) is pulverized: Glu, alanine, Ac-Di-Sol, microcrystalline cellulose, dolomol are mixed, and the fine powder mixed obtaining various material after pulverizer is pulverized is for subsequent use;
Step 2) mixing: get Arabinose, pour into together with the mixing fine powders for subsequent use in step 1) in double-cone mixer, mix 30-40 minutes, make it even;
Step 3) compressing tablet: by step 2) mixing fine powders that obtains inserts in tablet press machine and carries out compressing tablet, obtained tablet;
Step 4) dressing: get coating agent maltitol, fully dissolve with pure water, obtained coating solution, then utilizes high efficiency smart atresia seed-coating machine to carry out film coating to the tablet of step 3), obtained Arabinose drunk-sobering tablet finished product;
The weight of the raw material of above-mentioned use is as follows:
Arabinose 10-60 parts, Glu 5-15 parts, alanine 2-10 parts, Ac-Di-Sol 2-8 parts, microcrystalline cellulose 1-5 parts, dolomol 0.3-3 parts, maltitol 5-50 parts.
In described step 1), after pulverizer is pulverized, powder particle size is 60-150 orders.
Controlling tablet press machine pressure in described step 3) is 0.6-0.9MPa, and sheet weighs 1.0-2.0g.
A kind of Arabinose drunk-sobering tablet of the present invention compared to the prior art, this Arabinose drunk-sobering tablet take Arabinose as primary raw material, with Glu, alanine for auxiliary material, Arabinose drunk-sobering tablet is prepared by operations such as pulverizing, mixing, compressing tablet, dressings, raw materials usedly be green, health, human body had to great advantage, and mouthfeel is good, solubility is good, is easily accepted by consumers in general.After taking, without the need to decomposing, directly absorb, rapid-action, solution a series of discomforts after drinking can be alleviated rapidly, namely reach jubilant drinking, protect again health not by the object of alcohol injury.This product is not containing any pigment simultaneously, without sucrose, safety is without any side effects, diabetes patient also can relievedly eat, and for the people do not drunk, takes 3-5 these products every day, also be extraordinary for health, therefore say, Arabinose drunk-sobering tablet of the present invention has wide market, remarkable in economical benefits.
Detailed description of the invention
Embodiment 1:
1) get Glu 5g, alanine 2g, Ac-Di-Sol 2g, microcrystalline cellulose 1g, dolomol 0.3g, mix, after Universalpulverizer is pulverized, cross 60 object sub-sieves, obtain mixing fine powders 8g;
2) get powder Arabinose 10g, pour into together with above-mentioned mixing fine powders in double-cone mixer, mix 30 minutes, make it even;
3) insert in tablet press machine by the mixing fine powders of 2, control tableting pressure is 0.6MPa, carries out compressing tablet to mixing fine powders, obtains 15, tablet, every agreement that contracts a film or TV play to an actor or actress 1.0g;
4) get maltitol 5g, add 2ml pure water and fully dissolve, prepare coating solution, then utilize high efficiency smart atresia seed-coating machine to carry out film coating to tablet, obtained Arabinose drunk-sobering tablet finished product, every blade heavily about 1.3g.
Embodiment 2:
1) get Glu 15g, alanine 10g, Ac-Di-Sol 8g, microcrystalline cellulose 5g, dolomol 3g, mix, after Universalpulverizer is pulverized, cross 150 object sub-sieves, obtain mixing fine powders 40g;
2) get powder Arabinose 60g, pour into together with above-mentioned mixing fine powders in double-cone mixer, mix 40 minutes, make it even;
3) insert in tablet press machine by the mixing fine powders of 2, control tableting pressure is 0.9MPa, carries out compressing tablet to mixing fine powders, obtains 45, tablet, every agreement that contracts a film or TV play to an actor or actress 2.0g;
4) get maltitol 50g, add 20ml pure water and fully dissolve, prepare coating solution, then utilize high efficiency smart atresia seed-coating machine to carry out film coating to tablet, obtained Arabinose drunk-sobering tablet finished product, every blade heavily about 3g.
Embodiment: 3:
1) get Glu 10g, alanine 6g, Ac-Di-Sol 5g, microcrystalline cellulose 3g, dolomol 1.6g, mix, after Universalpulverizer is pulverized, cross 120 object sub-sieves, obtain mixing fine powders 23g;
2) get powder Arabinose 35g, pour into together with above-mentioned mixing fine powders in double-cone mixer, mix 35 minutes, make it even;
3) insert in tablet press machine by the mixing fine powders of 2, control tableting pressure is 0.75MPa, carries out compressing tablet to mixing fine powders, obtains 38, tablet, every agreement that contracts a film or TV play to an actor or actress 1.5g;
4) get maltitol 27g, add 11ml pure water and fully dissolve, prepare coating solution, then utilize high efficiency smart atresia seed-coating machine to carry out film coating to tablet, obtained Arabinose drunk-sobering tablet finished product, every blade heavily about 2.2g.
By detailed description of the invention above, described those skilled in the art can be easy to realize the present invention.But should be appreciated that the present invention is not limited to above-mentioned several detailed description of the invention.On the basis of disclosed embodiment, described those skilled in the art can be combined different technical characteristics, thus realize different technical schemes.
Claims (4)
1. an Arabinose drunk-sobering tablet, it is characterized in that, this Arabinose drunk-sobering tablet is with Arabinose, Glu and alanine for major ingredient, with Ac-Di-Sol, microcrystalline cellulose, dolomol and maltitol for auxiliary material is prepared from;
Formulation weight part proportioning of described major ingredient and auxiliary material is as follows:
Arabinose 10-60 parts, Glu 5-15 parts, alanine 2-10 parts, Ac-Di-Sol 2-8 parts, microcrystalline cellulose 1-5 parts, dolomol 0.3-3 parts, maltitol 5-50 parts.
2. a preparation method for Arabinose drunk-sobering tablet, is characterized in that, preparation method's step of this Arabinose drunk-sobering tablet is as follows:
Following procedure of processing is carried out in the clean area of purification:
Step 1) is pulverized: Glu, alanine, Ac-Di-Sol, microcrystalline cellulose, dolomol are mixed, and the fine powder mixed obtaining various material after pulverizer is pulverized is for subsequent use;
Step 2) mixing: get Arabinose, pour into together with the mixing fine powders for subsequent use in step 1) in double-cone mixer, mix 30-40 minutes, make it even;
Step 3) compressing tablet: by step 2) mixing fine powders that obtains inserts in tablet press machine and carries out compressing tablet, obtained tablet;
Step 4) dressing: get coating agent maltitol, fully dissolve with pure water, obtained coating solution, then utilizes high efficiency smart atresia seed-coating machine to carry out film coating to the tablet of step 3), obtained Arabinose drunk-sobering tablet finished product;
The weight of the raw material of above-mentioned use is as follows:
Arabinose 10-60 parts, Glu 5-15 parts, alanine 2-10 parts, Ac-Di-Sol 2-8 parts, microcrystalline cellulose 1-5 parts, dolomol 0.3-3 parts, maltitol 5-50 parts.
3. the preparation method of a kind of Arabinose drunk-sobering tablet according to claim 2, is characterized in that, in described step 1), after pulverizer is pulverized, powder particle size is 60-150 orders.
4. the preparation method of a kind of Arabinose drunk-sobering tablet according to claim 2, is characterized in that, controlling tablet press machine pressure in described step 3) is 0.6-0.9MPa, and sheet weighs 1.0-2.0g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510488054.1A CN105010937A (en) | 2015-08-11 | 2015-08-11 | L-arabinose anti-alcohol pill and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510488054.1A CN105010937A (en) | 2015-08-11 | 2015-08-11 | L-arabinose anti-alcohol pill and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105010937A true CN105010937A (en) | 2015-11-04 |
Family
ID=54401548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510488054.1A Pending CN105010937A (en) | 2015-08-11 | 2015-08-11 | L-arabinose anti-alcohol pill and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105010937A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106262942A (en) * | 2016-08-22 | 2017-01-04 | 山东福田药业有限公司 | A kind of drunk-sobering tablet and preparation method thereof |
| CN107828618A (en) * | 2017-12-05 | 2018-03-23 | 济南圣泉唐和唐生物科技有限公司 | A kind of health-care spirit |
| CN108634323A (en) * | 2018-05-12 | 2018-10-12 | 益家元品实业（厦门）有限公司 | Chewable tablets and its production technology |
| CN108653716A (en) * | 2018-07-20 | 2018-10-16 | 武汉友酵生物技术有限公司 | A kind of tealeaves essence drunk-sobering tablet and preparation method thereof |
| CN111990641A (en) * | 2020-05-06 | 2020-11-27 | 焦作百仑斯生物科技有限公司 | Alcohol-dispelling liver-protecting tablet and construction method thereof |
| CN113973961A (en) * | 2021-10-27 | 2022-01-28 | 上海圣岳生物科技有限公司 | Pressed candy for promoting ubiquitination metabolic pathway of human body and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271739A1 (en) * | 2004-06-08 | 2005-12-08 | Wang Xiang H | Methods and compositions for accelerating alcohol metabolism |
| CN101766635A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101797023A (en) * | 2009-11-26 | 2010-08-11 | 济南圣泉唐和唐生物科技有限公司 | Application of L-arabinopyranose as dealcoholic agent |
| CN102058047A (en) * | 2010-12-31 | 2011-05-18 | 济南圣泉唐和唐生物科技有限公司 | Health care product for relieving alcoholic liver |
| CN103445175A (en) * | 2013-09-17 | 2013-12-18 | 深圳万和制药有限公司 | Composition with effects of alleviating hangover and protecting liver |
-
2015
- 2015-08-11 CN CN201510488054.1A patent/CN105010937A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271739A1 (en) * | 2004-06-08 | 2005-12-08 | Wang Xiang H | Methods and compositions for accelerating alcohol metabolism |
| CN1706479A (en) * | 2004-06-08 | 2005-12-14 | 美国酶医公司 | Methods and compositions for accelerating alcohol metabolism |
| CN101766635A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101797023A (en) * | 2009-11-26 | 2010-08-11 | 济南圣泉唐和唐生物科技有限公司 | Application of L-arabinopyranose as dealcoholic agent |
| CN102058047A (en) * | 2010-12-31 | 2011-05-18 | 济南圣泉唐和唐生物科技有限公司 | Health care product for relieving alcoholic liver |
| CN103445175A (en) * | 2013-09-17 | 2013-12-18 | 深圳万和制药有限公司 | Composition with effects of alleviating hangover and protecting liver |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106262942A (en) * | 2016-08-22 | 2017-01-04 | 山东福田药业有限公司 | A kind of drunk-sobering tablet and preparation method thereof |
| CN107828618A (en) * | 2017-12-05 | 2018-03-23 | 济南圣泉唐和唐生物科技有限公司 | A kind of health-care spirit |
| CN108634323A (en) * | 2018-05-12 | 2018-10-12 | 益家元品实业（厦门）有限公司 | Chewable tablets and its production technology |
| CN108653716A (en) * | 2018-07-20 | 2018-10-16 | 武汉友酵生物技术有限公司 | A kind of tealeaves essence drunk-sobering tablet and preparation method thereof |
| CN111990641A (en) * | 2020-05-06 | 2020-11-27 | 焦作百仑斯生物科技有限公司 | Alcohol-dispelling liver-protecting tablet and construction method thereof |
| CN113973961A (en) * | 2021-10-27 | 2022-01-28 | 上海圣岳生物科技有限公司 | Pressed candy for promoting ubiquitination metabolic pathway of human body and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105010937A (en) | L-arabinose anti-alcohol pill and preparation method thereof | |
| JP6064156B2 (en) | Deep body temperature raising agent | |
| ES2539453T3 (en) | Preparations with rose hip extracts as well as procedures for preparing rose hip extracts | |
| CN102599322A (en) | Tablet candy suitable for children and manufacturing method thereof | |
| CN106975069A (en) | A kind of liver protecting composition and preparation method thereof | |
| JP2005325025A (en) | Diabetes-preventing/treating composition | |
| JP6211500B2 (en) | Brown adipocyte activator | |
| JP5725638B2 (en) | Body heat production promoter | |
| CN103652913B (en) | Jujube, rhizoma dioscoreae and fructus lycii chewable tablets and preparation method | |
| CN101687003B (en) | Novel pharmaceutical composition for use as a laxative | |
| CN105595148A (en) | Acanthopanax trifoliatus effervescence solid drink and preparing method thereof | |
| CN106983787A (en) | It is a kind of to have by composition of stasis of blood function and preparation method thereof | |
| JP6765090B2 (en) | Black ginger-containing composition | |
| CN108653716A (en) | A kind of tealeaves essence drunk-sobering tablet and preparation method thereof | |
| CN101721673A (en) | Preparation for soothing liver, regulating Qi, reducing phlegm and relieving sore throat and preparation method thereof | |
| TW201318566A (en) | Composition and method of delivery of l-arabinose and select compounds | |
| JP6108352B2 (en) | Fatigue improving composition | |
| US20160287656A1 (en) | Herbaceutical Formulations | |
| JP2005304369A (en) | Health supplement containing panax ginseng, ganoderma lucidum or extract thereof | |
| CN106176901A (en) | A kind of astragalus chewable tablets and preparation method thereof | |
| TWI344844B (en) | Antacid compositions | |
| CN110710672A (en) | Natural plant active calcium preparation and preparation method thereof | |
| JP4818549B2 (en) | Aldose reductase inhibitor | |
| TW202019456A (en) | Composition capable of nourishing yin and nourishing kidney as well as preparation method and application of composition | |
| EP2441333B1 (en) | Chewable tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151104 |
|
| RJ01 | Rejection of invention patent application after publication |